glun2a antibody Search Results


94
Alomone Labs nr2a
Figure 1. Clinical features and immunoglobulin G (IgG) binding to conformational neuronal surface epitopes from plasma and cerebrospinal fluid (CSF) of patients with neuropsychiatric lupus (NPSLE). A. Clinical features of 35 patients with SLE, including 15 with active NPSLE at the time of sampling. 32/34 (94%) were on immunotherapies, including prednisolone (71%), hydroxychloroquine (41%), belimumab (6%) and rituximab (3%). ANA = anti-nuclear antibody. B. Live cell-based assays employing HEK293T cells with surface expressed N-methyl D-aspartate receptors (NMDARs) as <t>NR1-NR2A</t> or NR1-NR2B heteromers (nuclei highlighted with DAPI, 4′,6-diamidino-2-phenylindole). First panel shows that a commercial antibody directed against the extracellular domain of the NR2A-subunit (red) binds to HEK293T cells which express NR1-NR2A heteromers. NMDAR-antibody encephalitis (NMDAR-Ab-E) patient serum IgGs (n=11) bind to the NR1-NR2A heteromers (second panel), and to NR1-NR2B heteromers / NR1 homomers (data not shown). NMDAR-antibody patient CSFs show similar binding (as Irani et al, 2010).10 Serum from healthy controls (n=36), plasma and CSFs from SLE patients (n=35 of each) show no binding. No binding was observed with the G11 antibody (data not shown, lower panel representative). Throughout, IgG binding was visualized with an anti-human 568-Alexaflour antibody (1:750 dilution, A-21090) C. Commercial antibodies against the extracellular domains of NR1 (Alomone, AGC-001), NR2A (Alomone,
Nr2a, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/glun2a+antibody/Anti-NMDAR2A+(GluN2A)+(extracellular)+Antibody/pm32951275-110-24-25
Average 94 stars, based on 1 article reviews
nr2a - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

94
NeuroMab mouse anti glun2a
Figure 1. Clinical features and immunoglobulin G (IgG) binding to conformational neuronal surface epitopes from plasma and cerebrospinal fluid (CSF) of patients with neuropsychiatric lupus (NPSLE). A. Clinical features of 35 patients with SLE, including 15 with active NPSLE at the time of sampling. 32/34 (94%) were on immunotherapies, including prednisolone (71%), hydroxychloroquine (41%), belimumab (6%) and rituximab (3%). ANA = anti-nuclear antibody. B. Live cell-based assays employing HEK293T cells with surface expressed N-methyl D-aspartate receptors (NMDARs) as <t>NR1-NR2A</t> or NR1-NR2B heteromers (nuclei highlighted with DAPI, 4′,6-diamidino-2-phenylindole). First panel shows that a commercial antibody directed against the extracellular domain of the NR2A-subunit (red) binds to HEK293T cells which express NR1-NR2A heteromers. NMDAR-antibody encephalitis (NMDAR-Ab-E) patient serum IgGs (n=11) bind to the NR1-NR2A heteromers (second panel), and to NR1-NR2B heteromers / NR1 homomers (data not shown). NMDAR-antibody patient CSFs show similar binding (as Irani et al, 2010).10 Serum from healthy controls (n=36), plasma and CSFs from SLE patients (n=35 of each) show no binding. No binding was observed with the G11 antibody (data not shown, lower panel representative). Throughout, IgG binding was visualized with an anti-human 568-Alexaflour antibody (1:750 dilution, A-21090) C. Commercial antibodies against the extracellular domains of NR1 (Alomone, AGC-001), NR2A (Alomone,
Mouse Anti Glun2a, supplied by NeuroMab, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/glun2a+antibody/Anti-GluN2A-NR2A+Antibody/pmc07480244-116-56-60
Average 94 stars, based on 1 article reviews
mouse anti glun2a - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

94
Alomone Labs anti nmdar2a glun2a
Immunostaining for cholera toxin β-subunit (CTB) and <t>NMDAR2A</t> in the suprachiasmatic nucleus (SCN) from wild-type (WT) and Shank3 +/– mice. CTB (diaminobenzidine, DAB, left column ) and NMDAR2A ( right column ) did not show obvious differences in the immunoreactivity between groups (WT, top micrographs ; Shank3 +/– , bottom micrographs ). For this and subsequent figures ( , ), scale bar = 50 μm.
Anti Nmdar2a Glun2a, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/glun2a+antibody/Anti-NMDAR2A+(GluN2A)+(extracellular)+Antibody+-+Carrier+Free/pmc07930753-84-41-49
Average 94 stars, based on 1 article reviews
anti nmdar2a glun2a - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc antibodies for glun2a
Immunostaining for cholera toxin β-subunit (CTB) and <t>NMDAR2A</t> in the suprachiasmatic nucleus (SCN) from wild-type (WT) and Shank3 +/– mice. CTB (diaminobenzidine, DAB, left column ) and NMDAR2A ( right column ) did not show obvious differences in the immunoreactivity between groups (WT, top micrographs ; Shank3 +/– , bottom micrographs ). For this and subsequent figures ( , ), scale bar = 50 μm.
Antibodies For Glun2a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/glun2a+antibody/NMDA+Receptor+2A+(GluN2A)+Antibody/10__1523_slash_JNEUROSCI__1414___21__2021_ascii32_-111-19-24
Average 95 stars, based on 1 article reviews
antibodies for glun2a - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

93
Proteintech glun2a
Immunostaining for cholera toxin β-subunit (CTB) and <t>NMDAR2A</t> in the suprachiasmatic nucleus (SCN) from wild-type (WT) and Shank3 +/– mice. CTB (diaminobenzidine, DAB, left column ) and NMDAR2A ( right column ) did not show obvious differences in the immunoreactivity between groups (WT, top micrographs ; Shank3 +/– , bottom micrographs ). For this and subsequent figures ( , ), scale bar = 50 μm.
Glun2a, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/glun2a+antibody/NMDAR2A%2FGRIN2A+Antibody/pmc03834217-241-29-32
Average 93 stars, based on 1 article reviews
glun2a - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc phospho glun2a
FIGURE 5 Administration of (2R,6R)-HNK reverses opioid abstinence-induced impaired synaptic plasticity markers in the ventral hippocampus. (a) Timeline for the experimental procedures. Following a 3-week abstinence period from an escalating-dose morphine regime (20– 100 mgkg1), mice received a single injection of saline or (2R,6R)-HNK (10 mgkg1). Subsequent western blot analysis of synaptoneurosomal fractions of ventral hippocampus of these mice revealed that protracted morphine abstinence induces significant reductions in (b) <t>GluN2A</t> subunits of the NMDA receptors. This effect was reversed by administration of (2R,6R)-HNK (10 mgkg1). (c) Protracted morphine abstinence did not alter mTOR levels, but significantly reduced phosphorylated mTOR levels; (2R,6R)-HNK administration did not reverse this effect of opioid abstinence. (d) Similarly, (2R,6R)-HNK administration did not reverse reductions induced by protracted morphine abstinence in GluN1 subunit levels of the NMDA receptors. (e) Protracted morphine abstinence induced a significant decrease in brain-derived neurotrophic factor (BDNF) levels, which (2R,6R)-HNK reversed. Data shown are individual values with means ± SEM; n = 10 mice per group; * P < 0.05. For uncropped Western blot images, please refer to the supporting information, which specify the exact representative images utilized in the analysis in red. Representative images were re-arranged, using examples from non-adjacent lanes to keep treatment order. Statistical tests and results are detailed in Table S8. Also, see Figure S7. Abbreviations: BDNF, brain-derived neurotrophic factor; GluN1, GluN1 NMDA receptor subunit; GluN2A, GluN2A NMDA receptor subunit; HNK, hydroxynorketamine; MOR, morphine; mTOR, mechanistic target of rapamycin; SAL, saline; SPT, sucrose preference test.
Phospho Glun2a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/glun2a+antibody/Phospho-NMDA+Receptor+2A+(GluN2A)+(Tyr1246)+Antibody/pm40155780-267-81-84
Average 93 stars, based on 1 article reviews
phospho glun2a - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

90
Alomone Labs α nr2a
FIGURE 5 Administration of (2R,6R)-HNK reverses opioid abstinence-induced impaired synaptic plasticity markers in the ventral hippocampus. (a) Timeline for the experimental procedures. Following a 3-week abstinence period from an escalating-dose morphine regime (20– 100 mgkg1), mice received a single injection of saline or (2R,6R)-HNK (10 mgkg1). Subsequent western blot analysis of synaptoneurosomal fractions of ventral hippocampus of these mice revealed that protracted morphine abstinence induces significant reductions in (b) <t>GluN2A</t> subunits of the NMDA receptors. This effect was reversed by administration of (2R,6R)-HNK (10 mgkg1). (c) Protracted morphine abstinence did not alter mTOR levels, but significantly reduced phosphorylated mTOR levels; (2R,6R)-HNK administration did not reverse this effect of opioid abstinence. (d) Similarly, (2R,6R)-HNK administration did not reverse reductions induced by protracted morphine abstinence in GluN1 subunit levels of the NMDA receptors. (e) Protracted morphine abstinence induced a significant decrease in brain-derived neurotrophic factor (BDNF) levels, which (2R,6R)-HNK reversed. Data shown are individual values with means ± SEM; n = 10 mice per group; * P < 0.05. For uncropped Western blot images, please refer to the supporting information, which specify the exact representative images utilized in the analysis in red. Representative images were re-arranged, using examples from non-adjacent lanes to keep treatment order. Statistical tests and results are detailed in Table S8. Also, see Figure S7. Abbreviations: BDNF, brain-derived neurotrophic factor; GluN1, GluN1 NMDA receptor subunit; GluN2A, GluN2A NMDA receptor subunit; HNK, hydroxynorketamine; MOR, morphine; mTOR, mechanistic target of rapamycin; SAL, saline; SPT, sucrose preference test.
α Nr2a, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/glun2a+antibody/Anti-NMDAR2A+(GluN2A)+(extracellular)-ATTO+Fluor-488+Antibody/pmc03915878-113-7-9
Average 90 stars, based on 1 article reviews
α nr2a - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

93
Boster Bio nr2a
FIGURE 5 Administration of (2R,6R)-HNK reverses opioid abstinence-induced impaired synaptic plasticity markers in the ventral hippocampus. (a) Timeline for the experimental procedures. Following a 3-week abstinence period from an escalating-dose morphine regime (20– 100 mgkg1), mice received a single injection of saline or (2R,6R)-HNK (10 mgkg1). Subsequent western blot analysis of synaptoneurosomal fractions of ventral hippocampus of these mice revealed that protracted morphine abstinence induces significant reductions in (b) <t>GluN2A</t> subunits of the NMDA receptors. This effect was reversed by administration of (2R,6R)-HNK (10 mgkg1). (c) Protracted morphine abstinence did not alter mTOR levels, but significantly reduced phosphorylated mTOR levels; (2R,6R)-HNK administration did not reverse this effect of opioid abstinence. (d) Similarly, (2R,6R)-HNK administration did not reverse reductions induced by protracted morphine abstinence in GluN1 subunit levels of the NMDA receptors. (e) Protracted morphine abstinence induced a significant decrease in brain-derived neurotrophic factor (BDNF) levels, which (2R,6R)-HNK reversed. Data shown are individual values with means ± SEM; n = 10 mice per group; * P < 0.05. For uncropped Western blot images, please refer to the supporting information, which specify the exact representative images utilized in the analysis in red. Representative images were re-arranged, using examples from non-adjacent lanes to keep treatment order. Statistical tests and results are detailed in Table S8. Also, see Figure S7. Abbreviations: BDNF, brain-derived neurotrophic factor; GluN1, GluN1 NMDA receptor subunit; GluN2A, GluN2A NMDA receptor subunit; HNK, hydroxynorketamine; MOR, morphine; mTOR, mechanistic target of rapamycin; SAL, saline; SPT, sucrose preference test.
Nr2a, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/glun2a+antibody/Anti-NMDAR2A%2FGRIN2A+Antibody+Picoband/10__14336_slash_ad__2023__0228-103-44-45
Average 93 stars, based on 1 article reviews
nr2a - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

92
Boster Bio anti nr2a antibody
<t>NR2A</t> and NR2B antagonists prevented and reversed mechanical allodynia in rats with SNI. a The threshold force of SNI-induced mechanical allodynia on the ipsilateral hind paw was significantly decreased on day 7 and continued until day 14. Intrathecal treatment with the NR2A-selective antagonist NVP-AAM077 (4 nmol) and the NR2B-selective antagonist Ro25-6981 (20 nmol) once daily for 14 days prevented the development of mechanical allodynia on the hind paw ipsilateral to SNI on days 3, 5, 7, 10, and 14. c A single intrathecal administration of NVP-AAM077 (4 nmol) and Ro25-6981 (20 nmol) on day 14 attenuated mechanical allodynia at 30 min after the treatment, and the effect of NVP-AAM077 was maintained for 24 h. b , d NVP-AAM077 and Ro25-6981 did not change the mechanical nociceptive threshold of the contralateral hind paw in the same rat. e A single intrathecal administration of 10 nmol MK-801 on day 14 reversed SNI-induced mechanical allodynia 30 min after the treatment. NVP, NVP-AAM077; Ro25, Ro25-6981; MK, MK-801. Data are shown as the means ± SE. * P < 0.05, ** P < 0.01 versus vehicle. # P < 0.05, ## P < 0.01 versus before the single intrathecal treatment
Anti Nr2a Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/glun2a+antibody/Anti-Phospho-NMDA+Receptor+NR2A+Subunit+(Tyr1325)+GRIN2A+Antibody/pmc07878206-88-14-16
Average 92 stars, based on 1 article reviews
anti nr2a antibody - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

90
Merck KGaA anti-glun2a monoclonal antibody
Ethanol place preferences is associated with the expression of mRNA from <t>GluN2A</t> but not from GluN1 subunit in the NAc. A , Schematic of the experimental design. B , Place preference elicited by the administration of 70 nmol of ethanol in the pVTA. Data are mean ± SEM represented as preference score (test minus pretest time spent in ethanol-paired compartment). * denotes significant differences between means (p<0.01, t-Test). C , Diagram of brain coronal sections indicating in blue the area of all microinjections in pVTA. D , Expression of mRNA from NMDA subunits GluN1 and GluN2A in NAc after ethanol induced CPP. Data are mean ± SEM represented as number of dots (mRNA molecules) per cell. * denotes significant differences between means (p<0.05). E , Expression of mRNA from NMDA subunits GluN1 and GluN2A in hippocampus after ethanol induced CPP. Data are mean ± SEM represented as number of dots (mRNA molecules) per cell.
Anti Glun2a Monoclonal Antibody, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/glun2a+antibody/anti+glun2a+monoclonal+antibody/bio_rxiv__2020__01__07__897702-92-36-40
Average 90 stars, based on 1 article reviews
anti-glun2a monoclonal antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
ZenBio nmda receptor subunit n2a (glun2a
Ethanol place preferences is associated with the expression of mRNA from <t>GluN2A</t> but not from GluN1 subunit in the NAc. A , Schematic of the experimental design. B , Place preference elicited by the administration of 70 nmol of ethanol in the pVTA. Data are mean ± SEM represented as preference score (test minus pretest time spent in ethanol-paired compartment). * denotes significant differences between means (p<0.01, t-Test). C , Diagram of brain coronal sections indicating in blue the area of all microinjections in pVTA. D , Expression of mRNA from NMDA subunits GluN1 and GluN2A in NAc after ethanol induced CPP. Data are mean ± SEM represented as number of dots (mRNA molecules) per cell. * denotes significant differences between means (p<0.05). E , Expression of mRNA from NMDA subunits GluN1 and GluN2A in hippocampus after ethanol induced CPP. Data are mean ± SEM represented as number of dots (mRNA molecules) per cell.
Nmda Receptor Subunit N2a (Glun2a, supplied by ZenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/glun2a+antibody/nmda+receptor+subunit+n2a++glun2a+antibody/pmc11239537-74-42-44
Average 90 stars, based on 1 article reviews
nmda receptor subunit n2a (glun2a - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

94
Boster Bio polyclonal rabbit antibody to nr2b
Ethanol place preferences is associated with the expression of mRNA from <t>GluN2A</t> but not from GluN1 subunit in the NAc. A , Schematic of the experimental design. B , Place preference elicited by the administration of 70 nmol of ethanol in the pVTA. Data are mean ± SEM represented as preference score (test minus pretest time spent in ethanol-paired compartment). * denotes significant differences between means (p<0.01, t-Test). C , Diagram of brain coronal sections indicating in blue the area of all microinjections in pVTA. D , Expression of mRNA from NMDA subunits GluN1 and GluN2A in NAc after ethanol induced CPP. Data are mean ± SEM represented as number of dots (mRNA molecules) per cell. * denotes significant differences between means (p<0.05). E , Expression of mRNA from NMDA subunits GluN1 and GluN2A in hippocampus after ethanol induced CPP. Data are mean ± SEM represented as number of dots (mRNA molecules) per cell.
Polyclonal Rabbit Antibody To Nr2b, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/glun2a+antibody/Anti-Phospho-NMDA+Receptor+NR2B+Subunit+(Ser1166)+Grin2b+Antibody/pm20422365-91-5-10
Average 94 stars, based on 1 article reviews
polyclonal rabbit antibody to nr2b - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


Figure 1. Clinical features and immunoglobulin G (IgG) binding to conformational neuronal surface epitopes from plasma and cerebrospinal fluid (CSF) of patients with neuropsychiatric lupus (NPSLE). A. Clinical features of 35 patients with SLE, including 15 with active NPSLE at the time of sampling. 32/34 (94%) were on immunotherapies, including prednisolone (71%), hydroxychloroquine (41%), belimumab (6%) and rituximab (3%). ANA = anti-nuclear antibody. B. Live cell-based assays employing HEK293T cells with surface expressed N-methyl D-aspartate receptors (NMDARs) as NR1-NR2A or NR1-NR2B heteromers (nuclei highlighted with DAPI, 4′,6-diamidino-2-phenylindole). First panel shows that a commercial antibody directed against the extracellular domain of the NR2A-subunit (red) binds to HEK293T cells which express NR1-NR2A heteromers. NMDAR-antibody encephalitis (NMDAR-Ab-E) patient serum IgGs (n=11) bind to the NR1-NR2A heteromers (second panel), and to NR1-NR2B heteromers / NR1 homomers (data not shown). NMDAR-antibody patient CSFs show similar binding (as Irani et al, 2010).10 Serum from healthy controls (n=36), plasma and CSFs from SLE patients (n=35 of each) show no binding. No binding was observed with the G11 antibody (data not shown, lower panel representative). Throughout, IgG binding was visualized with an anti-human 568-Alexaflour antibody (1:750 dilution, A-21090) C. Commercial antibodies against the extracellular domains of NR1 (Alomone, AGC-001), NR2A (Alomone,

Journal: Annals of neurology

Article Title: Absence of Neuronal Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus.

doi: 10.1002/ana.25908

Figure Lengend Snippet: Figure 1. Clinical features and immunoglobulin G (IgG) binding to conformational neuronal surface epitopes from plasma and cerebrospinal fluid (CSF) of patients with neuropsychiatric lupus (NPSLE). A. Clinical features of 35 patients with SLE, including 15 with active NPSLE at the time of sampling. 32/34 (94%) were on immunotherapies, including prednisolone (71%), hydroxychloroquine (41%), belimumab (6%) and rituximab (3%). ANA = anti-nuclear antibody. B. Live cell-based assays employing HEK293T cells with surface expressed N-methyl D-aspartate receptors (NMDARs) as NR1-NR2A or NR1-NR2B heteromers (nuclei highlighted with DAPI, 4′,6-diamidino-2-phenylindole). First panel shows that a commercial antibody directed against the extracellular domain of the NR2A-subunit (red) binds to HEK293T cells which express NR1-NR2A heteromers. NMDAR-antibody encephalitis (NMDAR-Ab-E) patient serum IgGs (n=11) bind to the NR1-NR2A heteromers (second panel), and to NR1-NR2B heteromers / NR1 homomers (data not shown). NMDAR-antibody patient CSFs show similar binding (as Irani et al, 2010).10 Serum from healthy controls (n=36), plasma and CSFs from SLE patients (n=35 of each) show no binding. No binding was observed with the G11 antibody (data not shown, lower panel representative). Throughout, IgG binding was visualized with an anti-human 568-Alexaflour antibody (1:750 dilution, A-21090) C. Commercial antibodies against the extracellular domains of NR1 (Alomone, AGC-001), NR2A (Alomone,

Article Snippet: Throughout, IgG binding was visualized with an anti-human 568-Alexaflour antibody (1:750 dilution, A-21090) C. Commercial antibodies against the extracellular domains of NR1 (Alomone, AGC-001), NR2A (Alomone, AGC-002) and NR2B (kind gift from Prof Stephenson, London) subunits bound to the surface of live HEK293T cells co-transfected with EGFP plus NR1 and NR2B subunits.

Techniques: Binding Assay, Clinical Proteomics, Sampling

Immunostaining for cholera toxin β-subunit (CTB) and NMDAR2A in the suprachiasmatic nucleus (SCN) from wild-type (WT) and Shank3 +/– mice. CTB (diaminobenzidine, DAB, left column ) and NMDAR2A ( right column ) did not show obvious differences in the immunoreactivity between groups (WT, top micrographs ; Shank3 +/– , bottom micrographs ). For this and subsequent figures ( , ), scale bar = 50 μm.

Journal: Frontiers in Neuroscience

Article Title: Altered Light Sensitivity of Circadian Clock in Shank3 +/– Mouse

doi: 10.3389/fnins.2021.604165

Figure Lengend Snippet: Immunostaining for cholera toxin β-subunit (CTB) and NMDAR2A in the suprachiasmatic nucleus (SCN) from wild-type (WT) and Shank3 +/– mice. CTB (diaminobenzidine, DAB, left column ) and NMDAR2A ( right column ) did not show obvious differences in the immunoreactivity between groups (WT, top micrographs ; Shank3 +/– , bottom micrographs ). For this and subsequent figures ( , ), scale bar = 50 μm.

Article Snippet: Primary antibodies were diluted as indicated in 0.1 M PBS containing 1.0% normal serum in 0.3% Triton X-100 [anti-VIP raised in rabbit, CAT 20077, Incstar, 1:2,000 ( ); anti-CTB subunit raised in goat, CAT 703, List Biological Laboratories, 1:2,000 ( ); anti-NMDAR2A (GluN2A) raised in rabbit, CAT ACG 002, Alomone Labs, 1:400 ( ); and anti c-FOS raised in rabbit, CAT SC-52, Santa Cruz, 1:1,000 ( )].

Techniques: Immunostaining

FIGURE 5 Administration of (2R,6R)-HNK reverses opioid abstinence-induced impaired synaptic plasticity markers in the ventral hippocampus. (a) Timeline for the experimental procedures. Following a 3-week abstinence period from an escalating-dose morphine regime (20– 100 mgkg1), mice received a single injection of saline or (2R,6R)-HNK (10 mgkg1). Subsequent western blot analysis of synaptoneurosomal fractions of ventral hippocampus of these mice revealed that protracted morphine abstinence induces significant reductions in (b) GluN2A subunits of the NMDA receptors. This effect was reversed by administration of (2R,6R)-HNK (10 mgkg1). (c) Protracted morphine abstinence did not alter mTOR levels, but significantly reduced phosphorylated mTOR levels; (2R,6R)-HNK administration did not reverse this effect of opioid abstinence. (d) Similarly, (2R,6R)-HNK administration did not reverse reductions induced by protracted morphine abstinence in GluN1 subunit levels of the NMDA receptors. (e) Protracted morphine abstinence induced a significant decrease in brain-derived neurotrophic factor (BDNF) levels, which (2R,6R)-HNK reversed. Data shown are individual values with means ± SEM; n = 10 mice per group; * P < 0.05. For uncropped Western blot images, please refer to the supporting information, which specify the exact representative images utilized in the analysis in red. Representative images were re-arranged, using examples from non-adjacent lanes to keep treatment order. Statistical tests and results are detailed in Table S8. Also, see Figure S7. Abbreviations: BDNF, brain-derived neurotrophic factor; GluN1, GluN1 NMDA receptor subunit; GluN2A, GluN2A NMDA receptor subunit; HNK, hydroxynorketamine; MOR, morphine; mTOR, mechanistic target of rapamycin; SAL, saline; SPT, sucrose preference test.

Journal: British journal of pharmacology

Article Title: (2R,6R)-hydroxynorketamine prevents opioid abstinence-related negative affect and stress-induced reinstatement in mice.

doi: 10.1111/bph.70018

Figure Lengend Snippet: FIGURE 5 Administration of (2R,6R)-HNK reverses opioid abstinence-induced impaired synaptic plasticity markers in the ventral hippocampus. (a) Timeline for the experimental procedures. Following a 3-week abstinence period from an escalating-dose morphine regime (20– 100 mgkg1), mice received a single injection of saline or (2R,6R)-HNK (10 mgkg1). Subsequent western blot analysis of synaptoneurosomal fractions of ventral hippocampus of these mice revealed that protracted morphine abstinence induces significant reductions in (b) GluN2A subunits of the NMDA receptors. This effect was reversed by administration of (2R,6R)-HNK (10 mgkg1). (c) Protracted morphine abstinence did not alter mTOR levels, but significantly reduced phosphorylated mTOR levels; (2R,6R)-HNK administration did not reverse this effect of opioid abstinence. (d) Similarly, (2R,6R)-HNK administration did not reverse reductions induced by protracted morphine abstinence in GluN1 subunit levels of the NMDA receptors. (e) Protracted morphine abstinence induced a significant decrease in brain-derived neurotrophic factor (BDNF) levels, which (2R,6R)-HNK reversed. Data shown are individual values with means ± SEM; n = 10 mice per group; * P < 0.05. For uncropped Western blot images, please refer to the supporting information, which specify the exact representative images utilized in the analysis in red. Representative images were re-arranged, using examples from non-adjacent lanes to keep treatment order. Statistical tests and results are detailed in Table S8. Also, see Figure S7. Abbreviations: BDNF, brain-derived neurotrophic factor; GluN1, GluN1 NMDA receptor subunit; GluN2A, GluN2A NMDA receptor subunit; HNK, hydroxynorketamine; MOR, morphine; mTOR, mechanistic target of rapamycin; SAL, saline; SPT, sucrose preference test.

Article Snippet: Transferred proteins were blocked with 5% milk in TBST (TBS plus 0.1% Tween-20) for 1 h and incubated in primary antibodies (1:1000 in 5% BSA) overnight at 4 C. The following primary antibodies were use: phospho-eEF2 (at Thr56; Cell Signalling Technology; #2331; RRID:AB_10015204), total eEF2 (Cell Signalling Technology; #2332; RRID:AB_10693546), phospho-mTOR (at Ser2448; Cell Signalling Technology; #2971; RRID:AB_330970), total mTOR (Cell Signalling Technology; #2983; RRID:AB_2105622), phospho-GluA1 (at Ser831; Cell Signalling Technology; #75574; RRID: AB_2799873), GluA1 (Cell Signalling Technology; #13185; RRID:AB_ 2732897), phospho-GluN2A (at Tyr1246; Cell Signalling Technology; #4206; RRID:AB_2112292), GluN2A (Cell Signalling Technology; #4205; RRID:AB_2112295), GluN1 (Cell Signalling Technology; #5704; RRID:AB_1904067), BDNF (Cell Signalling Technology; #47808; RRID: AB_2894709), and GAPDH (Cell Signalling Technology; #97166; RRID: AB_2756824).

Techniques: Injection, Saline, Western Blot, Derivative Assay

NR2A and NR2B antagonists prevented and reversed mechanical allodynia in rats with SNI. a The threshold force of SNI-induced mechanical allodynia on the ipsilateral hind paw was significantly decreased on day 7 and continued until day 14. Intrathecal treatment with the NR2A-selective antagonist NVP-AAM077 (4 nmol) and the NR2B-selective antagonist Ro25-6981 (20 nmol) once daily for 14 days prevented the development of mechanical allodynia on the hind paw ipsilateral to SNI on days 3, 5, 7, 10, and 14. c A single intrathecal administration of NVP-AAM077 (4 nmol) and Ro25-6981 (20 nmol) on day 14 attenuated mechanical allodynia at 30 min after the treatment, and the effect of NVP-AAM077 was maintained for 24 h. b , d NVP-AAM077 and Ro25-6981 did not change the mechanical nociceptive threshold of the contralateral hind paw in the same rat. e A single intrathecal administration of 10 nmol MK-801 on day 14 reversed SNI-induced mechanical allodynia 30 min after the treatment. NVP, NVP-AAM077; Ro25, Ro25-6981; MK, MK-801. Data are shown as the means ± SE. * P < 0.05, ** P < 0.01 versus vehicle. # P < 0.05, ## P < 0.01 versus before the single intrathecal treatment

Journal: Molecular Neurobiology

Article Title: Leptin Contributes to Neuropathic Pain via Extrasynaptic NMDAR-nNOS Activation

doi: 10.1007/s12035-020-02180-1

Figure Lengend Snippet: NR2A and NR2B antagonists prevented and reversed mechanical allodynia in rats with SNI. a The threshold force of SNI-induced mechanical allodynia on the ipsilateral hind paw was significantly decreased on day 7 and continued until day 14. Intrathecal treatment with the NR2A-selective antagonist NVP-AAM077 (4 nmol) and the NR2B-selective antagonist Ro25-6981 (20 nmol) once daily for 14 days prevented the development of mechanical allodynia on the hind paw ipsilateral to SNI on days 3, 5, 7, 10, and 14. c A single intrathecal administration of NVP-AAM077 (4 nmol) and Ro25-6981 (20 nmol) on day 14 attenuated mechanical allodynia at 30 min after the treatment, and the effect of NVP-AAM077 was maintained for 24 h. b , d NVP-AAM077 and Ro25-6981 did not change the mechanical nociceptive threshold of the contralateral hind paw in the same rat. e A single intrathecal administration of 10 nmol MK-801 on day 14 reversed SNI-induced mechanical allodynia 30 min after the treatment. NVP, NVP-AAM077; Ro25, Ro25-6981; MK, MK-801. Data are shown as the means ± SE. * P < 0.05, ** P < 0.01 versus vehicle. # P < 0.05, ## P < 0.01 versus before the single intrathecal treatment

Article Snippet: Membranes were blocked with 5% nonfat dried milk and incubated overnight (4 °C) with anti-NR2A antibody (BOSTER, China: 1:400, rabbit polyclonal), anti-NR2B antibody (Abcam, USA: 1:1000, rabbit polyclonal) [ ] and anti-nNOS antibody (BD Biosciences, USA: 1:1000, mouse monoclonal).

Techniques:

NR2A and NR2B antagonists prevented exogenous leptin-induced mechanical allodynia. a Intrathecal leptin (50 μg) treatment in naïve rats, given once daily for 7 days, induced mechanical allodynia on day 7. Coadministration of leptin with 4 nmol NVP-AAM077 or 20 nmol Ro25-6981 attenuated the behavioral changes ( n = 5). b NVP-AAM077 and Ro25-6981 alone did not change the baseline nociceptive threshold ( n = 6). lep, leptin; NVP, NVP-AAM077; Ro25, Ro25-6981. Data are shown as the means ± SE. ** P < 0.01 versus day 0

Journal: Molecular Neurobiology

Article Title: Leptin Contributes to Neuropathic Pain via Extrasynaptic NMDAR-nNOS Activation

doi: 10.1007/s12035-020-02180-1

Figure Lengend Snippet: NR2A and NR2B antagonists prevented exogenous leptin-induced mechanical allodynia. a Intrathecal leptin (50 μg) treatment in naïve rats, given once daily for 7 days, induced mechanical allodynia on day 7. Coadministration of leptin with 4 nmol NVP-AAM077 or 20 nmol Ro25-6981 attenuated the behavioral changes ( n = 5). b NVP-AAM077 and Ro25-6981 alone did not change the baseline nociceptive threshold ( n = 6). lep, leptin; NVP, NVP-AAM077; Ro25, Ro25-6981. Data are shown as the means ± SE. ** P < 0.01 versus day 0

Article Snippet: Membranes were blocked with 5% nonfat dried milk and incubated overnight (4 °C) with anti-NR2A antibody (BOSTER, China: 1:400, rabbit polyclonal), anti-NR2B antibody (Abcam, USA: 1:1000, rabbit polyclonal) [ ] and anti-nNOS antibody (BD Biosciences, USA: 1:1000, mouse monoclonal).

Techniques:

Leptin enhancement of NR2B- but not NR2A-mediated currents in dissociated lamina II neurons in naïve rats. a Treatment with the NR2A-selective antagonist NVP-AAM077 (0.4 μM) plus the NR2B-selective antagonist Ro25-6981 (1 μM) blocked NMDAR-mediated currents ( n = 8). b Exposure to leptin (100 nM) for 5 min did not change NMDAR-mediated currents after blockade with Ro25-6981 (1 μM) ( n = 10). c Exposure to leptin (100 nM) for 5 min enhanced NMDAR-mediated currents after inhibition by 0.4 μM NVP-AAM077 ( n = 9). d Histograms showing the effect of leptin on NMDAR-mediated currents after inhibition by NVP-AAM077 or Ro25-6981. Data are shown as the means ± SE. lep, leptin; NVP, NVP-AAM077; Ro, Ro25-6981. * P < 0.05, ** P < 0.01 vs. vehicle; # P < 0.05 vs NVP

Journal: Molecular Neurobiology

Article Title: Leptin Contributes to Neuropathic Pain via Extrasynaptic NMDAR-nNOS Activation

doi: 10.1007/s12035-020-02180-1

Figure Lengend Snippet: Leptin enhancement of NR2B- but not NR2A-mediated currents in dissociated lamina II neurons in naïve rats. a Treatment with the NR2A-selective antagonist NVP-AAM077 (0.4 μM) plus the NR2B-selective antagonist Ro25-6981 (1 μM) blocked NMDAR-mediated currents ( n = 8). b Exposure to leptin (100 nM) for 5 min did not change NMDAR-mediated currents after blockade with Ro25-6981 (1 μM) ( n = 10). c Exposure to leptin (100 nM) for 5 min enhanced NMDAR-mediated currents after inhibition by 0.4 μM NVP-AAM077 ( n = 9). d Histograms showing the effect of leptin on NMDAR-mediated currents after inhibition by NVP-AAM077 or Ro25-6981. Data are shown as the means ± SE. lep, leptin; NVP, NVP-AAM077; Ro, Ro25-6981. * P < 0.05, ** P < 0.01 vs. vehicle; # P < 0.05 vs NVP

Article Snippet: Membranes were blocked with 5% nonfat dried milk and incubated overnight (4 °C) with anti-NR2A antibody (BOSTER, China: 1:400, rabbit polyclonal), anti-NR2B antibody (Abcam, USA: 1:1000, rabbit polyclonal) [ ] and anti-nNOS antibody (BD Biosciences, USA: 1:1000, mouse monoclonal).

Techniques: Inhibition

Leptin enhancement of NR2B, but not NR2A, expression in cultured DRG neurons. a Immunohistochemistry results showed that administration of leptin in culture medium for 72 h upregulated NR2B expression in a dose-dependent manner (2 ng/ml leptin had the maximal enhancement effect), and cotreatment with 1 μM Ro25-6981 diminished the upregulation. b Leptin at 2 ng/ml slightly enhanced NR2A expression, which was attenuated by 0.4 μM NVP-AAM077. c – f Western blot results showed that administration of leptin (2 ng/ml) to culture medium for 72 h significantly upregulated NR2B expression ( c , d ) but not NR2A expression ( e , f ) in cultured DRG neurons. The NR2B upregulation was blocked by 1 μM Ro25-6981 ( c , d ). Neither 1 μM Ro25-6981 nor 0.4 μM NVP-AAM077 alone changed the baseline expression of NR2B or NR2A. lep, leptin; NVP, NVP-AAM077; Ro, Ro25-6981. n = 3. Scale bar, 50 μm. * P < 0.05 vs vehicle

Journal: Molecular Neurobiology

Article Title: Leptin Contributes to Neuropathic Pain via Extrasynaptic NMDAR-nNOS Activation

doi: 10.1007/s12035-020-02180-1

Figure Lengend Snippet: Leptin enhancement of NR2B, but not NR2A, expression in cultured DRG neurons. a Immunohistochemistry results showed that administration of leptin in culture medium for 72 h upregulated NR2B expression in a dose-dependent manner (2 ng/ml leptin had the maximal enhancement effect), and cotreatment with 1 μM Ro25-6981 diminished the upregulation. b Leptin at 2 ng/ml slightly enhanced NR2A expression, which was attenuated by 0.4 μM NVP-AAM077. c – f Western blot results showed that administration of leptin (2 ng/ml) to culture medium for 72 h significantly upregulated NR2B expression ( c , d ) but not NR2A expression ( e , f ) in cultured DRG neurons. The NR2B upregulation was blocked by 1 μM Ro25-6981 ( c , d ). Neither 1 μM Ro25-6981 nor 0.4 μM NVP-AAM077 alone changed the baseline expression of NR2B or NR2A. lep, leptin; NVP, NVP-AAM077; Ro, Ro25-6981. n = 3. Scale bar, 50 μm. * P < 0.05 vs vehicle

Article Snippet: Membranes were blocked with 5% nonfat dried milk and incubated overnight (4 °C) with anti-NR2A antibody (BOSTER, China: 1:400, rabbit polyclonal), anti-NR2B antibody (Abcam, USA: 1:1000, rabbit polyclonal) [ ] and anti-nNOS antibody (BD Biosciences, USA: 1:1000, mouse monoclonal).

Techniques: Expressing, Cell Culture, Immunohistochemistry, Western Blot

Leptin-mediated enhancement of nNOS expression was blocked by an NR2B antagonist. Immunohistochemistry ( a ) and Western blot ( b and c ) results showed that administration of leptin (2 ng/ml) to culture medium for 72 h significantly upregulated nNOS expression in cultured DRG neurons. The upregulation of nNOS expression by leptin was significantly prevented by coapplication of the NR2B antagonist Ro25-6981 (1 μM) and slightly attenuated by the NR2A antagonist NVP-AAM077 (0.4 μM). Ro25-6981 (1 μM) and NVP-AAM077 (0.4 μM) alone did not change baseline nNOS expression. Lep, leptin; NVP, NVP-AAM077; Ro, Ro25-6981. n = 3. Scale bar, 50 μm. ** P < 0.01 vs vehicle; # P < 0.05 vs leptin

Journal: Molecular Neurobiology

Article Title: Leptin Contributes to Neuropathic Pain via Extrasynaptic NMDAR-nNOS Activation

doi: 10.1007/s12035-020-02180-1

Figure Lengend Snippet: Leptin-mediated enhancement of nNOS expression was blocked by an NR2B antagonist. Immunohistochemistry ( a ) and Western blot ( b and c ) results showed that administration of leptin (2 ng/ml) to culture medium for 72 h significantly upregulated nNOS expression in cultured DRG neurons. The upregulation of nNOS expression by leptin was significantly prevented by coapplication of the NR2B antagonist Ro25-6981 (1 μM) and slightly attenuated by the NR2A antagonist NVP-AAM077 (0.4 μM). Ro25-6981 (1 μM) and NVP-AAM077 (0.4 μM) alone did not change baseline nNOS expression. Lep, leptin; NVP, NVP-AAM077; Ro, Ro25-6981. n = 3. Scale bar, 50 μm. ** P < 0.01 vs vehicle; # P < 0.05 vs leptin

Article Snippet: Membranes were blocked with 5% nonfat dried milk and incubated overnight (4 °C) with anti-NR2A antibody (BOSTER, China: 1:400, rabbit polyclonal), anti-NR2B antibody (Abcam, USA: 1:1000, rabbit polyclonal) [ ] and anti-nNOS antibody (BD Biosciences, USA: 1:1000, mouse monoclonal).

Techniques: Expressing, Immunohistochemistry, Western Blot, Cell Culture

Ethanol place preferences is associated with the expression of mRNA from GluN2A but not from GluN1 subunit in the NAc. A , Schematic of the experimental design. B , Place preference elicited by the administration of 70 nmol of ethanol in the pVTA. Data are mean ± SEM represented as preference score (test minus pretest time spent in ethanol-paired compartment). * denotes significant differences between means (p<0.01, t-Test). C , Diagram of brain coronal sections indicating in blue the area of all microinjections in pVTA. D , Expression of mRNA from NMDA subunits GluN1 and GluN2A in NAc after ethanol induced CPP. Data are mean ± SEM represented as number of dots (mRNA molecules) per cell. * denotes significant differences between means (p<0.05). E , Expression of mRNA from NMDA subunits GluN1 and GluN2A in hippocampus after ethanol induced CPP. Data are mean ± SEM represented as number of dots (mRNA molecules) per cell.

Journal: bioRxiv

Article Title: Dose-Dependent Induction Of CPP Or CPA By Intra-pVTA Ethanol: Role Of Mu Opioid Receptors And Effects On NMDA Receptors

doi: 10.1101/2020.01.07.897702

Figure Lengend Snippet: Ethanol place preferences is associated with the expression of mRNA from GluN2A but not from GluN1 subunit in the NAc. A , Schematic of the experimental design. B , Place preference elicited by the administration of 70 nmol of ethanol in the pVTA. Data are mean ± SEM represented as preference score (test minus pretest time spent in ethanol-paired compartment). * denotes significant differences between means (p<0.01, t-Test). C , Diagram of brain coronal sections indicating in blue the area of all microinjections in pVTA. D , Expression of mRNA from NMDA subunits GluN1 and GluN2A in NAc after ethanol induced CPP. Data are mean ± SEM represented as number of dots (mRNA molecules) per cell. * denotes significant differences between means (p<0.05). E , Expression of mRNA from NMDA subunits GluN1 and GluN2A in hippocampus after ethanol induced CPP. Data are mean ± SEM represented as number of dots (mRNA molecules) per cell.

Article Snippet: Membranes were then blocked in 5% non-fat dried milk in TBS-Tween-20 (TBS-T) 0.1% (20mM Tris and 500mM NaCl pH 7.5) and incubated overnight at 4°C with the primary antibody: anti-GluN1 (1:1000; Merck KGaA, Darmstadt, Germany) and anti-GluN2A monoclonal antibody (1:1000; Merck KGaA, Darmstadt, Germany).

Techniques: Expressing

Representative pictures of the compilation files obtained in the mRNA In Situ Hybridization Assay used for the quantification of mRNA from GluN1 and GluN2A subunits in NAc (left) and hippocampus (right) after ethanol induced CPP. Squares delimit the area of the amplified pictures shown in for the NAc and in for the hippocampus. Abbreviatures: Aca , anterior commissure; CA3 , field CA3 of hippocampus; DG , dentate gyrus; CA1 , field CA1 of hippocampus.

Journal: bioRxiv

Article Title: Dose-Dependent Induction Of CPP Or CPA By Intra-pVTA Ethanol: Role Of Mu Opioid Receptors And Effects On NMDA Receptors

doi: 10.1101/2020.01.07.897702

Figure Lengend Snippet: Representative pictures of the compilation files obtained in the mRNA In Situ Hybridization Assay used for the quantification of mRNA from GluN1 and GluN2A subunits in NAc (left) and hippocampus (right) after ethanol induced CPP. Squares delimit the area of the amplified pictures shown in for the NAc and in for the hippocampus. Abbreviatures: Aca , anterior commissure; CA3 , field CA3 of hippocampus; DG , dentate gyrus; CA1 , field CA1 of hippocampus.

Article Snippet: Membranes were then blocked in 5% non-fat dried milk in TBS-Tween-20 (TBS-T) 0.1% (20mM Tris and 500mM NaCl pH 7.5) and incubated overnight at 4°C with the primary antibody: anti-GluN1 (1:1000; Merck KGaA, Darmstadt, Germany) and anti-GluN2A monoclonal antibody (1:1000; Merck KGaA, Darmstadt, Germany).

Techniques: In Situ Hybridization, Amplification

Representative amplified pictures obtained in the mRNA In Situ Hybridization Assay used for the quantification of mRNA from GluN1 and GluN2A subunits in NAc. Amplified pictures from one animal of each group (aCSF on the left and ethanol 70 nmol on the right) were selected.

Journal: bioRxiv

Article Title: Dose-Dependent Induction Of CPP Or CPA By Intra-pVTA Ethanol: Role Of Mu Opioid Receptors And Effects On NMDA Receptors

doi: 10.1101/2020.01.07.897702

Figure Lengend Snippet: Representative amplified pictures obtained in the mRNA In Situ Hybridization Assay used for the quantification of mRNA from GluN1 and GluN2A subunits in NAc. Amplified pictures from one animal of each group (aCSF on the left and ethanol 70 nmol on the right) were selected.

Article Snippet: Membranes were then blocked in 5% non-fat dried milk in TBS-Tween-20 (TBS-T) 0.1% (20mM Tris and 500mM NaCl pH 7.5) and incubated overnight at 4°C with the primary antibody: anti-GluN1 (1:1000; Merck KGaA, Darmstadt, Germany) and anti-GluN2A monoclonal antibody (1:1000; Merck KGaA, Darmstadt, Germany).

Techniques: Amplification, In Situ Hybridization

Representative amplified pictures obtained in the mRNA In Situ Hybridization Assay used for the quantification of mRNA from GluN1 and GluN2A subunits in hippocampus. Amplified pictures from one animal of each group (aCSF on the left and ethanol 70 nmol on the right) were selected.

Journal: bioRxiv

Article Title: Dose-Dependent Induction Of CPP Or CPA By Intra-pVTA Ethanol: Role Of Mu Opioid Receptors And Effects On NMDA Receptors

doi: 10.1101/2020.01.07.897702

Figure Lengend Snippet: Representative amplified pictures obtained in the mRNA In Situ Hybridization Assay used for the quantification of mRNA from GluN1 and GluN2A subunits in hippocampus. Amplified pictures from one animal of each group (aCSF on the left and ethanol 70 nmol on the right) were selected.

Article Snippet: Membranes were then blocked in 5% non-fat dried milk in TBS-Tween-20 (TBS-T) 0.1% (20mM Tris and 500mM NaCl pH 7.5) and incubated overnight at 4°C with the primary antibody: anti-GluN1 (1:1000; Merck KGaA, Darmstadt, Germany) and anti-GluN2A monoclonal antibody (1:1000; Merck KGaA, Darmstadt, Germany).

Techniques: Amplification, In Situ Hybridization

Simplified representation of the dose-dependent ethanol effect on place preference or place aversion and its hypothesized mechanism. The administration of low doses of ethanol into the VTA does not induce preference or aversion for the drug paired compartment. Medium doses elicit CPP, presumably through an increase of the ethanol metabolized fraction. In our hypothesis and based in previous literature, the ethanol metabolite, salsolinol, would activate MORs, decreasing GABA release and finally increasing DA release in the NAc by a disinhibition of VTA DA neurons. The expression of ethanol induced CPP also results in an increase of mRNA form GluN2A in the NAc. Moreover, the blockade of the MORs in the VTA inhibits the acquisition of this ethanol induced CPP. However, the administration of high doses results in the development of CPA. In this case, the effect of the non-metabolized fraction would predominate and the inhibition of the VTA DA neurons would result in a decrease of DA release in the NAc. In orange GABA terminals and in purple VTA DA neurons. MOR: mu opioid receptor; GABAR: gamma-amino butyric acid (GABA) receptor; NAc: nucleus accumbens; VTA: ventral tegmental area; DA: dopamine; GLUN2A: NMDA receptor subunit 2A.

Journal: bioRxiv

Article Title: Dose-Dependent Induction Of CPP Or CPA By Intra-pVTA Ethanol: Role Of Mu Opioid Receptors And Effects On NMDA Receptors

doi: 10.1101/2020.01.07.897702

Figure Lengend Snippet: Simplified representation of the dose-dependent ethanol effect on place preference or place aversion and its hypothesized mechanism. The administration of low doses of ethanol into the VTA does not induce preference or aversion for the drug paired compartment. Medium doses elicit CPP, presumably through an increase of the ethanol metabolized fraction. In our hypothesis and based in previous literature, the ethanol metabolite, salsolinol, would activate MORs, decreasing GABA release and finally increasing DA release in the NAc by a disinhibition of VTA DA neurons. The expression of ethanol induced CPP also results in an increase of mRNA form GluN2A in the NAc. Moreover, the blockade of the MORs in the VTA inhibits the acquisition of this ethanol induced CPP. However, the administration of high doses results in the development of CPA. In this case, the effect of the non-metabolized fraction would predominate and the inhibition of the VTA DA neurons would result in a decrease of DA release in the NAc. In orange GABA terminals and in purple VTA DA neurons. MOR: mu opioid receptor; GABAR: gamma-amino butyric acid (GABA) receptor; NAc: nucleus accumbens; VTA: ventral tegmental area; DA: dopamine; GLUN2A: NMDA receptor subunit 2A.

Article Snippet: Membranes were then blocked in 5% non-fat dried milk in TBS-Tween-20 (TBS-T) 0.1% (20mM Tris and 500mM NaCl pH 7.5) and incubated overnight at 4°C with the primary antibody: anti-GluN1 (1:1000; Merck KGaA, Darmstadt, Germany) and anti-GluN2A monoclonal antibody (1:1000; Merck KGaA, Darmstadt, Germany).

Techniques: Expressing, Inhibition